Pharma BD Deal Intelligence
Celltech's CDP870 became Cimzia — a ~$2B/year blockbuster that anchored UCB's transformation into a biopharma company for two decades
Full analysis, sources & comparables →UCB launched a friendly £1.53B (~$2.7B) cash offer for Celltech, citing CDP870 and the antibody platform as creating Europe's #2 biopharma.
Nature Biotechnology characterized the Celltech acquisition as sending mixed messages on the UK biotech sector - validation of asset value but loss of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Friendly offer £1.53B (~$2.7B); UK biotech; CDP870 lead asset; created Europe's #2 biopharma
Celltech's CDP870 became Cimzia — a ~$2B/year blockbuster that anchored UCB's transformation into a biopharma company for two decades
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB SA / Celltech Group plc (this deal) | 2004 | $2.7B | 92 |
| UCB SA / Schwarz Pharma AG | 2006 | $5.6B | 80 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
← Browse all deals · How we score deals
More: 2004 deals · Gastroenterology deals